Category: 141774-61-0

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.141774-61-0,tert-Butyl (piperidin-2-ylmethyl)carbamate,as a common compound, the synthetic route is as follows.

To a solution of 2-[2-[[2-(2,6-dioxo-3-piperidyl)-1,3-dioxo-isoindolin-4-yl]amino]ethoxy]ethyl methanesulfonate (500 mg, 1.14 mmol, synthesized via Steps 1-2 of Example 184) in CH3CN (20 mL) was added tert-butyl N-(2-piperidylmethyl) carbamate (488 mg, 2.28 mmol, CAS141774-61-0), NaHCO3 (287 mg, 3.41 mmol) and KI (18.9 mg, 114 umol). The mixture was stirred at 80 C. for 16 hours. On completion, the mixture was concentrated in vacuo. The residue was purified by reversed phase flash to give the title compound (450 mg, 71% yield) as yellow solid. LC-MS (ESI+) m/z 558.4 (M+H)+.

141774-61-0, As the paragraph descriping shows that 141774-61-0 is playing an increasingly important role.

Reference：
Patent; Kymera Therapeutics, Inc.; Mainolfi, Nello; Ji, Nan; Kluge, Arthur F.; Weiss, Matthew M.; Zhang, Yi; (1443 pag.)US2019/192668; (2019); A1;,
Piperidine – Wikipedia
Piperidine | C5H11N – PubChem

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.141774-61-0,tert-Butyl (piperidin-2-ylmethyl)carbamate,as a common compound, the synthetic route is as follows.

A mixture of 2,4-dichloro-5-fluoropyrimidine (167 mg, 1.00 mmol), 2-N-Boc- aminomethyl piperidine (214 mg, 1.00 mmol) and DIEA (0.400 mL, 2.30 mmol) in CH3CN (4 mL) was stirred at room temperature for 20 h. It was concentrated in vacuo. The residue was dissolved in nBuOH (6 mL). 3 mL of the nBuOH solution was taken, to which l-(4-(4- aminophenyl)piperazin-l-yl)ethanone (142 mg, 0.65 mmol) was added. The solution was stirred at 116 0C for 20 h. nBuOH was removed in vacuo. The residue was purified by HPLC to give tert-butyl (l-(2-(4-(4-acetylpiperazin-l-yl)phenylamino)-5-fluoropyrimidin-4- yl)piperidin-2-yl)methylcarbamate (56 mg). MS 528.4 (M+H).

141774-61-0, As the paragraph descriping shows that 141774-61-0 is playing an increasingly important role.

Reference：
Patent; PORTOLA PHARMACEUTICALS, INC.; WO2009/131687; (2009); A2;,
Piperidine – Wikipedia
Piperidine | C5H11N – PubChem

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.141774-61-0,tert-Butyl (piperidin-2-ylmethyl)carbamate,as a common compound, the synthetic route is as follows.

To a solution of Compound L (14.71 g, 46.7 mmol) in THF(250 mE) at -60 C. was added 0.5 M KHMDS solution inTHF (103 mE) dropwise. After stirring at -60 C. for 30 mithe reaction mixture was added to a solution of 4-nitrophenylchloroformate at -60 C. (9.41 g, 46.7 mmol) in THF (200This reaction mixture was then stirred for 30 mm at -60C., followed by addition of piperidine-2-yl-methylcarbamicacid tert-butyl ester, also referred to herein as (R,S)-piperi-dine-2-yl-methylcarbamic acid tert-butyl ester, (5.0 g, 23.3mmol) in portions. The reaction was allowed to warm toambient temperature and then stirred for 18 h. The reactionwas then concentrated under vacuum, and the residue dilutedwith EtOAc (500 mE). The mixture was then washed withwater (2×250 mE) and brine (250 mE). The organic layer wasseparated, dried over Na2504, and filtered. Removal of sol-vents under vacuum afforded crude Compound N. CrudeCompound N was purified by flash chromatography using100% EtOAc. Removal of solvent under vacuum affordedCompound N in 50% yield (6.5 g, 11.7 mmol) as a whitesolid. EC-MS [M+H] 556.1 (C30H41N307+H, calc: 555.3)., 141774-61-0

The synthetic route of 141774-61-0 has been constantly updated, and we look forward to future research findings.

Reference：
Patent; Signature Therapeutics, Inc.; Jenkins, Thomas E.; Husfeld, Craig O.; US9139612; (2015); B2;,
Piperidine – Wikipedia
Piperidine | C5H11N – PubChem

141774-61-0, tert-Butyl (piperidin-2-ylmethyl)carbamate is a piperidines compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

141774-61-0, A. Methyl 2-(2-((tert-butoxycarbonylamino)methyl)piperidin-1-yl)-4-chloro-6-(m-tolylamino)pyrimidine-5-carboxylate A mixture of methyl 2,4-dichloro-6-(m-tolylamino)pyrimidine-5-carboxylate (600.6 mg, 1.924 mmol), tert-butyl piperidin-2-ylmethylcarbamate (500.9 mg, 2.337 mmol) and N-ethyl-N-isopropylpropan-2-amine (0.4 mL, 2.296 mmol) in DMF (10 mL) was stirred at 0 C. for 3 h. Water (50 mL) was added to the mixture, which was extracted with EtOAc (2×40 mL). The organic layers were washed with saturated aq NaHCO3 (20 mL), water (20 mL) and brine (20 mL), were dried over anhydrous Na2SO4, and then filtered (DM1020). The filtrate was concentrated under reduced pressure and the residue was purified by column chromatography (SiO2, hexanes/EtOAc=4/1) to give the title compound as a clear oil (310.5 mg). 1H NMR (500 MHz, CDCl3) delta ppm 1.34-1.74 (m, 15H), 2.35-2.37 (m, 3H), 3.03-3.21 (m, 2H), 3.60-3.71 (m, 1H), 3.90 (s, 3H), 4.43-5.04 (m, 3H), 6.94-6.98 (m, 1H), 7.23-7.46 (m, 3H), 10.13-10.43 (m, 1H). [M+H] calc’d for C24H33ClN5O4, 490. found, 490.

The synthetic route of 141774-61-0 has been constantly updated, and we look forward to future research findings.

Reference：
Patent; Takeda Pharmaceutical Company Limited; US2011/152273; (2011); A1;,
Piperidine – Wikipedia
Piperidine | C5H11N – PubChem

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.141774-61-0,tert-Butyl (piperidin-2-ylmethyl)carbamate,as a common compound, the synthetic route is as follows.

A solution of 4-nitrophenyl(4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)phenyl)carbamate (2.08 g), tert-butyl (piperidin-2-ylmethyl)carbamate (1.19 g) and TEA (2.20 mL) in N,N-dimethylacetamide (25.0 mL) was stirred at room temperature for 2 hr. To the reaction mixture was added water, and the mixture was extracted with ethyl acetate. The organic layer was washed with water and saturated brine, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (hexane/ethyl acetate) to give the title compound (2.17 g). 1H NMR (300 MHz, CDCl3) delta 1.36-1.54 (11H, m), 1.63-1.83 (4H, m), 2.70 (1H, t, J = 12.5 Hz), 3.12-3.28 (1H, m), 3.29-3.43 (1H, m), 4.03-4.22 (1H, m), 4.35 (1H, d, J = 12.5 Hz), 5.01 (1H, brs), 7.77 (2H, d, J = 8.7 Hz), 7.95-8.07 (2H, m), 8.56 (1H, brs) .

141774-61-0, The synthetic route of 141774-61-0 has been constantly updated, and we look forward to future research findings.

Reference：
Patent; Takeda Pharmaceutical Company Limited; KAIEDA, Akira; ISHII, Naoki; NARA, Hiroshi; YOSHIKAWA, Masato; DAINI, Masaki; (63 pag.)EP3342772; (2018); A1;,
Piperidine – Wikipedia
Piperidine | C5H11N – PubChem

141774-61-0, tert-Butyl (piperidin-2-ylmethyl)carbamate is a piperidines compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

DIPEA (O.lmL, 0.560mmol) and tert-butyl (piperidin-2-ylmethyl)carbamate (59.6 mg, 0.28mmol) were added to to a stirred solution of ethyl 4-(chlorosulfonyl)-3-fluoro-l-methyl-lH-pyrrole-2-carboxylate (50 mg, 0.l90mmol) in MeCN (l.84mL, 0.035mol) and stirring was continued overnight at room temperature. Volatiles were evaporated and the residue was partitioned between sat. NH4Cl solution and EtOAc. The organic layer was separated, dried over Na2S04, evaporated under reduced pressure and purified by flash cromatography on silica gel (Petroleum ether/EtOAc) to give ethyl 4-((2-(((tert-butoxycarbonyl)amino)methyl)piperidin-l-yl)sulfonyl)-3-fluoro-l- methyl-lH-pyrrole-2-carboxylate (77.82 mg, y= 93.8%). Method 1: Rt=2.l5min. m/z=348.l8 (M- l00)+ Exact mass=447.l8. The Boc protecting group was removed by dissolving the intermediate ethyl 4-((2-(((tert-butoxycarbonyl)amino)methyl)piperidin-1-yl)sulfonyl)-3-fluoro-1-methyl-1H- pyrrole-2-carboxylate in dioxane (l.7mL) and treating with hydrogen chloride 4N in dioxane (2.8lmL,l l.25mmol) at RT for lh. Volatiles were evaporated under reduced pressure to afford D39 as HC1 salt, in about quantitative yield (66.75 mg). Method 1 : Rt= l.l8min. m/z=348.l3 (M+H)+ Exact mass=347.l8., 141774-61-0

The synthetic route of 141774-61-0 has been constantly updated, and we look forward to future research findings.

Reference：
Patent; OSPEDALE SAN RAFFAELE S.R.L.; IRBM S.P.A.; PROMIDIS S.R.L.; ISTITUTO NAZIONALE DI GENETICA MOLECOLARE – INGM; DE FRANCESCO, Raffaele; DONNICI, Lorena; GUIDOTTI, Luca; IANNACONE, Matteo; DI FABIO, Romano; SUMMA, Vincenzo; PRANDI, Adolfo; RANDAZZO, Pietro; GORNATI, Davide; GRILLO, Alessandro; FERRANTE, Luca; BENCHEVA, Leda Ivanova; DE MATTEO, Marilenia; FERRARA, Marco; (238 pag.)WO2020/30781; (2020); A1;,
Piperidine – Wikipedia
Piperidine | C5H11N – PubChem

141774-61-0, tert-Butyl (piperidin-2-ylmethyl)carbamate is a piperidines compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

HATU (157 mg, 0.413 mmol)was added to a stirred solution of 2-(l -ethyl- lH-indol-2-yl)-l – methyl-lH-benzo[d]imidazole-5-carboxylic acid (110 mg, 0.344 mmol)in DMF (2 mL)followed by DIPEA (0.072 mL, 0.413 mmol). After 30 min of stirring at rt, (+l-)-tert- butyl (piperidin-2-ylmethyl)carbamate (81 mg, 0.379 mmol)was added to the reaction mixtureand this was stirred for 2 h at rt. The solvent was removed under reduced pressure and water (10 mL) was added to the residue. A cream white precipitate was filtered off and rinsed with water (2 x 5 mL). The precipitate was dried in a vacuum oven for 2 h, affording 220 mg (113%) of a cream solid (the Boc-protected product). The Boc-protected product was then taken up in DCM (5 mL)and treated with TFA (1.5 mL, 19.47 mmol). After 30 min of stirring at rt the solvent was removed under reduced pressure and the dark purple residue was loaded in MeOH on a 2 g SCX column (previously conditioned with MeOH). The column was washed with MeOH (3CV) and eluted with methanolic ammonia (2N) (3 CV). The ammonia fractions were combined and evaporated under reduced pressure. The residue (189 mg) was loaded in DCM on a 10 g SNAP silica column and purified by SP4 flash chromatography, eluting with a 0-10% methanolic ammonia (2N) in DCM(10 CV). The appropriate fractions were combined and evaporated in vacuo to give (+/-)-(2- (aminom ethyl )piperi din- 1 -yl)(2-( 1 -ethyl- lH-indol-2-yl)- 1 -methyl- lH-benzo[d]imidazol-5- yl)methanone (11.4 mg, 0.027 mmol, 7.97 % yield)as a whitesolid.LCMS (Method B): Rt = 0.80min, MH+ = 416.2., 141774-61-0

As the paragraph descriping shows that 141774-61-0 is playing an increasingly important role.

Reference：
Patent; GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED; AMANS, Dominique; ATKINSON, Stephen, John; BARKER, Michael, David; CAMPBELL, Matthew; DIALLO, Hawa; DOUAULT, Clement; GARTON, Neil, Stuart; LIDDLE, John; RENAUX, Jessica, Fanny; SHEPPARD, Robert, John; WALKER, Ann, Louise; WELLAWAY, Christopher, Roland; WILSON, David, Matthew; (284 pag.)WO2016/185279; (2016); A1;,
Piperidine – Wikipedia
Piperidine | C5H11N – PubChem

141774-61-0, tert-Butyl (piperidin-2-ylmethyl)carbamate is a piperidines compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

A reaction flask charged with capsaicin (1 eq) and ethyl acetate, cooled to 0 – 10 C, and then DIPEA (3 eq) was added followed by the addition of nitrophenylchloroformate (1.0 eq) as a solution in ethyl acetate at 0 – 10 C. The resulting mixture was stirred at 0 – 10 C for 15 min. Next, HOBt (0.1 eq) was added, followed by A-1 free base (1.2 eq) at 0 – 10 C. The resulting mixture was stirred overnight after warming to room temperature. The reaction mixture was worked up by successive extractions with IM aq. NaOH (3x), IM aq. HCl, water and finally brine solution. The resulting organic layer was removed, dried over sodium sulfate and filtered to afford A-2 in an ethyl acetate solution. The crude product was used in the following reaction without further manipulation., 141774-61-0

The synthetic route of 141774-61-0 has been constantly updated, and we look forward to future research findings.

Reference：
Patent; CONCENTRIC ANALGESICS, INC.; DONOVAN, John F.; HUSFELD, Craig; (120 pag.)WO2018/217937; (2018); A1;,
Piperidine – Wikipedia
Piperidine | C5H11N – PubChem